Combination of oncolytic adenovirus and dacarbazine enhances antitumor ability against uveal melanoma cells via cell cycle block
Combination of oncolytic adenovirus and dacarbazine enhances antitumor ability against uveal melanoma cells via cell cycle block
复制标题
溶瘤腺病毒和达卡巴嗪的组合通过细胞周期阻断增强对葡萄膜黑色素瘤细胞的抗肿瘤能力
DOI：
10.4161/cbt.13.2.18436
复制
发表时间：
2012-01-15
影响因子：
3.6
通讯作者：
Fan, Xianqun
中科院分区：
文献类型：
--
作者：
Cun, Biyun;Song, Xin;Fan, Xianqun
葡萄膜黑色素瘤是成人中最常见的原发性眼内恶性肿瘤;然而，目前的治疗方式，包括化疗，尚未成功。溶瘤病毒作为一种新兴的基因治疗工具，用于癌症治疗，因为它们特异性地杀死肿瘤细胞，同时保留正常细胞。溶瘤病毒H101已被中国国家食品药品监督管理局批准用于治疗某些恶性肿瘤。不幸的是，腺病毒的单一疗法在临床环境中表现出有限的功效。因此，溶瘤病毒与现有化学品组合的新型治疗策略正朝着潜在的临床用途发展。本研究选择溶瘤病毒H101与烷化剂达卡巴嗪（DTIC）联合作用于体外培养的葡萄膜黑色素瘤细胞。我们的研究结果表明，该组合通过诱导凋亡以外的细胞周期阻滞类型发挥协同抗肿瘤作用，而不会增强对正常细胞的毒性。进一步的研究是必要的，以阐明这种联合治疗的具体机制。我们的研究表明，病毒-化疗联合治疗葡萄膜黑色素瘤是可行的，是一种潜在的有前途的方法。
Uveal melanoma is the most common primary intraocular malignancy in adults; however, current therapeutic modalities, including chemotherapy, have not been successful. Oncolytic viruses serve as an emerging gene therapy tool for cancer treatment because they specifically kill tumor cells while sparing normal cells. The oncolytic virus H101 has been approved by the Chinese State Food and Drug Administration for the treatment of certain malignancies. Unfortunately, the monotherapy of adenovirus has demonstrated limited efficacy in a clinical setting. Thus, novel treatment strategies in which an oncolytic virus is combined with existing chemicals are advancing toward potential clinical use. In this study, we chose the combination of oncolytic virus H101 and the alkylating agent dacarbazine (DTIC) to treat uveal melanoma cells in vitro. Our results demonstrated that the combination exerted a synergistic antitumor effect without enhanced toxicity to normal cells via a type of cell cycle block other than the induction of apoptosis. Further investigation is warranted to elucidate the specific underlying mechanisms of this co-treatment therapy. Our study suggests the viro-chemo combination therapy is feasible and is a potentially promising approach for the treatment of uveal melanoma.